|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Regulatory effect of gut microbes on blood pressure显示文摘Hypertension is an important global public health issue because of its high morbidity as well as the increased risk of other diseases.Recent studies have indicated that the development of hypertension is related to the dysbiosis of the gut microbiota in both animals and humans.In this review,we outline the interaction between gut microbiota and hypertension,including gut microbial changes in hypertension,the effect of microbial dysbiosis on blood pressure(BP),indicators of gut microbial dysbiosis in hypertension,and the microbial genera that affect BP at the taxonomic level.For example,increases in Lactobacillus,Roseburia,Coprococcus,Akkermansia,and Bifidobacterium are associated with reduced BP,while increases in Streptococcus,Blautia,and Prevotella are associated with elevated BP.Furthermore,we describe the potential mechanisms involved in the regulation between gut microbiota and hypertension.Finally,we summarize the commonly used treatments of hypertension that are based on gut microbes,including fecal microbiota transfer,probiotics and prebiotics,antibiotics,and dietary supplements.This review aims to find novel potential genera for improving hypertension and give a direction for future studies on gut microbiota in hypertension. | Dong Yan Ye Sun Xiaoyue Zhou Wenhao Si Jieyu Liu Min Li Minna Wu | 2022 | Animal Models and Experimental Medicine2022，5，6： | 1 |
| 2 | Drug-microbiota interactions: an emerging priority for precision medicine显示文摘Individual variability in drug response(IVDR)can be a major cause of adverse drug reactions(ADRs)and prolonged therapy,resulting in a substantial health and economic burden.Despite extensive research in pharmacogenomics regarding the impact of individual genetic background on pharmacokinetics(PK)and pharmacodynamics(PD),genetic diversity explains only a limited proportion of IVDR.The role of gut microbiota,also known as the second genome,and its metabolites in modulating therapeutic outcomes in human diseases have been highlighted by recent studies.Consequently,the burgeoning field of pharmacomicrobiomics aims to explore the correlation between microbiota variation and IVDR or ADRs.This review presents an up-to-date overview of the intricate interactions between gut microbiota and classical therapeutic agents for human systemic diseases,including cancer,cardiovascular diseases(CVDs),endocrine diseases,and others.We summarise how microbiota,directly and indirectly,modify the absorption,distribution,metabolism,and excretion(ADME)of drugs.Conversely,drugs can also modulate the composition and function of gut microbiota,leading to changes in microbial metabolism and immune response.We also discuss the practical challenges,strategies,and opportunities in this field,emphasizing the critical need to develop an innovative approach to multi-omics,integrate various data types,including human and microbiota genomic data,as well as translate lab data into clinical practice.To sum up,pharmacomicrobiomics represents a promising avenue to address IVDR and improve patient outcomes,and further research in this field is imperative to unlock its full potential for precision medicine. | Qing Zhao Yao Chen Weihua Huang Honghao Zhou Wei Zhang | 2023 | Signal Transduction and Targeted Therapy2023，8，11： | 0 |
| 3 | The gut-cardiovascular connection: new era for cardiovascular therapy显示文摘Our gut microbiome is constituted by trillions of microorganisms including bacteria,archaea and eukaryotic microbes.Nowadays,gut microbiome has been gradually recognized as a new organ system that systemically and biochemically interact with the host.Accumulating evidence suggests that the imbalanced gut microbiome contributes to the dysregulation of immune system and the disruption of cardiovascular homeostasis.Specific microbiome profiles and altered intestinal permeability are often observed in the pathophysiology of cardiovascular diseases.Gut-derived metabolites,toxins,peptides and immune cell-derived cytokines play pivotal roles in the induction of inflammation and the pathogenesis of dysfunction of heart and vasculature.Impaired crosstalk between gut microbiome and multiple organ systems,such as gut-vascular,heart-gut,gut-liver and brain-gut axes,are associated with higher cardiovascular risks.Medications and strategies that restore healthy gut microbiome might therefore represent novel therapeutic options to lower the incidence of cardiovascular and metabolic disorders. | Chak Kwong Cheng Yu Huang | 2021 | Medical Review2021，1，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员